Complement C5

Complement C5

Complement C5 Overview

Molecule Name
Complement C5
Synonyms
Complement C5,C5,CPAMD4
Drug Development Progress
Drugs in Clinical Trials20
Approved Drugs8
Highest Development StageApproved
Target Synonym
C5a,Complement Component 5,ECLZB,Anaphylatoxin C5a Analog,C5a Anaphylatoxin,C5b,C5,Prepro-C5,CPAMD4,Complement C5,C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4,C5D
Background
Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Complement C5 Product List

Species
  • Human(5)
  • Cynomolgus(2)
  • Rat(2)
  • Mouse(1)
  • Rabbit(1)
Tag
  • His Tag(7)
  • His Tag & Avi Tag(3)
  • Fc Tag(1)
Host
  • HEK293(11)
Conjugate
  • Unconjugated(8)
  • Biotin-labeled(3)
Grade
  • RUO(11)
Low Endotoxin
  • Yes(1)
  • No(10)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&PriceAdd to Cart
Complement C5
Human Complement C5 Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$495.00

100ug
Complement C5
Rat Complement C5 Protein, His Tag
Rat
HEK293
SDS-PAGE
ELISA

$395.00

100ug
Complement C5
Mouse Complement C5 Protein, His Tag
Mouse
HEK293
SDS-PAGE
ELISA

$395.00

100ug
Complement C5
HOTAvitag
CO5-H82E9
Biotinylated Human Complement C5 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$470.00

25ug
Complement C5
Cynomolgus Complement C5 Protein, His Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$395.00

100ug
Complement C5
Avitag
CO5-C82E3
Biotinylated Cynomolgus Complement C5 Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
Complement C5
Human Complement C5 Protein, Fc Tag
Human
HEK293
SDS-PAGE
ELISA

$395.00

100ug
Complement C5
Human Complement C5 (w917s) Protein, His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$395.00

100ug
Complement C5
Human Complement C5 (R885H) Protein, His Tag
Human
HEK293
SDS-PAGE
ELISA

$395.00

100ug
Complement C5
Rabbit Complement C5 Protein, His Tag
Rabbit
HEK293
SDS-PAGE

$395.00

100ug
You Have Viewed 1-10 Of 11 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Eculizumab biosimilar (CinnaGen)Phase 3 ClinicalCinnagen
Hemoglobinuria, Paroxysmal
Details
Eculizumab biosimilar (IBC GENERIUM)Phase 3 ClinicalIbc Generium
Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal
Details
Eculizumab biosimilar (Biocad)BCD-148Phase 3 ClinicalBIOCAD JSC
Hemoglobinuria, Paroxysmal
Details
CemdisiranALN-CC5; AD-62643; ALN-62643; L96Phase 3 ClinicalAlnylam Pharmaceuticals Inc
Atypical Hemolytic Uremic Syndrome; Geographic Atrophy; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Macular Degeneration; Myasthenia Gravis; Myositis; Myositis, Inclusion Body
Details
TesidolumabNOV-4; LFG-316Phase 2 ClinicalMorphosys Ag, Novartis Pharma Ag
Geographic Atrophy; Hemoglobinuria, Paroxysmal; Macular Degeneration; Panuveitis; Rejection of renal transplantation; Uveitis, Intermediate; Uveitis, Posterior; Wet Macular Degeneration
Details
IM-101IM-101Phase 2 ClinicalImmunAbs Inc
Autoimmune Diseases; Myasthenia Gravis
Details
ABBV-6628ABBV-6628Phase 2 ClinicalAbbvie Inc
Geographic Atrophy; Macular Degeneration
Details
OCUL-101OCUL101Phase 2 ClinicalShenzhen Oukejian Biomedical Technology Co Ltd
Diabetic macular oedema; Geographic Atrophy; Macular Degeneration; Retinal Neovascularization
Details
KRIYA-825KRIYA-825; VV-14295Phase 2 ClinicalKriya Therapeutics Inc
Geographic Atrophy
Details
LP-005LP-005; RX-001Phase 2 ClinicalLongbio Pharma (Suzhou) Co Ltd
Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies
Details
Vensobafusp alfaP014; KP-104Phase 2 ClinicalKira Pharmaceuticals LLC
Glomerulonephritis; Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Erythematosus, Systemic; Thrombotic Microangiopathies
Details
OmoprubartCAN-106Phase 2 ClinicalBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
Genetic Diseases, Inborn; Hemoglobinuria, Paroxysmal
Details
ALXN-5500ALXN-5500Phase 1 ClinicalAlexion Pharmaceuticals Inc
Hemoglobinuria, Paroxysmal
Details
RLYB-116RLYB-116Phase 1 ClinicalAffibody Ab, Swedish Orphan Biovitrum (Sobi)
Autoimmune Diseases; Hematologic Diseases; Immune System Diseases; Inflammation
Details
SYH-2061SYH2061; SYH-2061Phase 1 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Complement-Mediated Diseases; Glomerulonephritis, IGA; Nephrosis
Details
NM3086NM3086; NM-3086Phase 1 ClinicalNovelMed Therapeutics Inc
Hemoglobinuria, Paroxysmal
Details
Eculizumab biosimilar (Turgut Ardika)TUR03; TUR-03Phase 1 ClinicalTurgut Ardika Pty Ltd
Details
EA-5EA-5; EA5Phase 1 ClinicalShandong Lanyi Pharmaceutical Technology Co Ltd
Antiphospholipid Syndrome; Hemoglobinuria, Paroxysmal; Kidney Diseases; Myasthenia Gravis; Thrombotic Microangiopathies
Details
RBD-7007RBD-7007Phase 1 ClinicalSuzhou Ribo Life Science Co Ltd
Glomerulonephritis, IGA
Details
eculizumab biosimilar(Isu Abxis)ISU-305Phase 1 ClinicalIsu Abxis Co Ltd
Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Avacincaptad pegol sodiumARC-1905; ARC-187ApprovedArchemix CorpZimura, IzervayUnited StatesMacular Degeneration; Geographic AtrophyIveric Bio Inc, Astellas Pharma Inc2023-08-04
Geographic Atrophy; Macular Degeneration; Polypoidal choroidal vasculopathy
Details
Zilucoplan SodiumRA-101495-SC; RA-101495; ZLP-AIApprovedRa Pharmaceuticals Inc, Ucb SaZILBRYSQ, Zilbrysq, 卓倍可JapanMyasthenia GravisUcb Japan Co Ltd2023-09-25
Amyotrophic Lateral Sclerosis; Coronavirus Disease 2019 (COVID-19); Hemoglobinuria, Paroxysmal; Muscular Diseases; Myasthenia Gravis
Details
CrovalimabRO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689ApprovedChugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd派圣凯, PiaskyMainland ChinaHemoglobinuria, ParoxysmalRoche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc2024-02-06
Anemia, Sickle Cell; Antiphospholipid Syndrome; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Hemoglobinuria, Paroxysmal
Details
RavulizumabALXN-1810; ALXN-1210ApprovedAlexion Pharmaceuticals Inc, Xencor IncUltomiris, 伟立瑞United StatesHemoglobinuria, ParoxysmalAlexion Pharmaceuticals Inc2018-12-21
Acute Kidney Injury; Acute Lung Injury; Amyotrophic Lateral Sclerosis; Atypical Hemolytic Uremic Syndrome; Coronavirus Disease 2019 (COVID-19); Delayed Graft Function; Dermatomyositis; Glomerulonephritis, IGA; Heart Diseases; Hemoglobinuria, Paroxysmal; Immunoglobulin A Vasculitis Associated Nephritis; Kidney Diseases; Kidney Failure, Chronic; Lupus Nephritis; Myasthenia Gravis; Neuromyelitis Optica; Pneumonia, Viral; Purpura, Schoenlein-Henoch; Rejection of renal transplantation; Renal Insufficiency, Chronic; Respiratory Distress Syndrome, Adult; Thrombotic Microangiopathies
Details
EculizumabLEX-98; h-5G1.1; 5G1-1; HAL-1ApprovedAlexion Pharmaceuticals IncSoliris, 舒立瑞United StatesHemoglobinuria, ParoxysmalAlexion Pharmaceuticals Inc2007-03-16
Anemia, Hemolytic, Autoimmune; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Asthma; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Diabetes Mellitus; End Stage Liver Disease; Glomerulonephritis, Membranoproliferative; Guillain-Barre Syndrome; HELLP Syndrome; Hemoglobinuria, Paroxysmal; Infant, Newborn, Diseases; Kidney Failure, Chronic; Macular Degeneration; Myasthenia Gravis; Nasopharyngeal Carcinoma; Neuromyelitis Optica; Parturition; Pre-Eclampsia; Rejection of renal transplantation; Rejection of organ transplantation; Thrombocytopenia; Urea Cycle Disorders, Inborn; Vagus Nerve Diseases
Details
PozelimabREGN-3918ApprovedRegeneron Pharmaceuticals IncVEOPOZUnited StatesProtein-Losing EnteropathiesRegeneron Pharmaceuticals Inc2023-08-18
Geographic Atrophy; Hemoglobinuria, Paroxysmal; Myasthenia Gravis; Protein-Losing Enteropathies
Details
Eculizumab biosimilar (Amgen)ABP-959ApprovedAmgen IncBKEMVUnited StatesHemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic SyndromeAmgen Inc2024-05-28
Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal
Details
Eculizumab biosimilar (Samsung Bioepis)SB-12; AM004; AMT-904; SB12ApprovedSamsung Bioepis Co LtdEpysqli, EPYSQLIEUAtypical Hemolytic Uremic Syndrome; Hemoglobinuria, ParoxysmalSamsung Bioepis Nl Bv2023-05-26
Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal
Details
Customer Reviews
  • 1***32022-08-10
    I tried to express this product myself and it didn’t work, so I purchased ACRO’s products for antibody screening. The binding activity is very good and method establishment is also going very smoothly. There is also complete technical support available to help us solve any problems that arise during our experiments.